Skip to content
Screener

Pacira BioSciences, Inc. PCRX Business Segments — Changes in contingent consideration

Similar metrics at other companies

Ryan Specialty Holdings logo
RYANReporting Segment — Change in contingent consideration
$27.29M+294%
Insmed logo
INSMReportable Segment — Change in fair value of contingent consideration
-$99.76M-269%
Pacific Biosciences of California logo
PACBReportable Segment — Change in fair value of contingent consideration
$0
Intuitive Machines, Inc. logo
LUNRReportable Segment — Change in fair value of contingent consideration liabilities
$521K
Ranger Energy Services logo
RNGRReportable Segment — Adjustment to contingent consideration
$400K
PAR Technology logo
PARReportable Segment — Adjustment to contingent consideration liability
-$5.4M

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$997.34M-11.9%
Enterprise value$1.26B+6.9%
P/E194.1×
P/S1.4×-0.2×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Adjusted general and administrative (1)25,71220,609
Stock-based compensation (1)13,53914,553
Amortization of acquired intangible assets14,32214,322
Changes in the fair value of contingent consideration(2,277)(2,675)
Legal settlement7,000
Other (2)8801,862
Total operating expenses170,474166,933
Total other (expense) income, net(1,904)6,716

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s business segments — changes in contingent consideration?
Pacira BioSciences, Inc. (PCRX) reported business segments — changes in contingent consideration of -$2.28M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — changes in contingent consideration changed year-over-year?
Pacira BioSciences, Inc.'s business segments — changes in contingent consideration increased by 14.9% year-over-year, from -$2.68M to -$2.28M.
What does business segments — changes in contingent consideration mean?
Reflects adjustments to the fair value of earn-out or milestone payment obligations related to past acquisitions within the segment. Changes in this metric indicate shifts in the expected achievement of performance targets or valuation assumptions for acquired businesses.

Ask your AI about Pacira BioSciences, Inc.'s business segments — changes in contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude